Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

New research finds pattern for detecting 'false-positive' ANA results

The presence of antinuclear antibodies (ANA) indicates the possibility of autoimmunity and the indirect immunofluorescence (IIF) assay on HEp-2 cells is the standard blood test (ANA-HEp-2) used to detect ANA. However, studies have shown that a "false-positive" ANA test occurs in up to 13% of healthy individuals. In such cases the test detects the presence of autoantibodies that apparently are not associated with autoimmunity.

4 Jan 2011

Interventions aimed at infants improve school readiness and achievement

Parent education programs delivered through pediatric primary care offices increased parent-child play and reading activities critical for child development and school readiness during infancy in at-risk families, according to two concurrent reports in the January issue of Archives of Pediatrics & Adolescent Medicine, one of the JAMA/Archives journals.

4 Jan 2011

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

A new study shows that vitamin D deficiency could be linked to the development and severity of certain autoimmune lung diseases.

4 Jan 2011

New ATS guidelines for treating fungal infection in adult pulmonary and critical care patients

The American Thoracic Society has released a new official clinical policy statement on the treatment of fungal infections in adult pulmonary and critical care patients.

4 Jan 2011

Sleep-deprived physicians not to perform elective surgeries without patient's consent

While regulations have been put in place to restrict the work hours of doctors in training, no such regulations exist for fully trained physicians. An editorial in this week's New England Journal of Medicine argues that sleep-deprived physicians should not be permitted to proceed with an elective surgery without a patient's informed, written consent.

30 Dec 2010

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

Centocor Ortho Biotech Inc. announced today that it has filed a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) requesting the approval of REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis (UC) in pediatric patients who have had an inadequate response to conventional therapy.

29 Dec 2010

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

CEL-SCI Corporation announced today that it has commenced its Phase III clinical trial for Multikine®, the Company's flagship immunotherapy. CEL-SCI has now completed all of the manufacturing and regulatory requirements to begin enrollment of the study.

29 Dec 2010

Santarus, Pharming submit RHUCIN BLA to FDA for treatment of HAE attacks

Specialty biopharmaceutical company Santarus, Inc. and biotech company Pharming Group NV today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) to obtain marketing approval for RHUCIN® (recombinant human C1 inhibitor) for the treatment of acute angioedema attacks in patients with Hereditary Angioedema (HAE).

29 Dec 2010

$Herbal pain medication gets fractured runner back running again$

Herbal pain medication gets fractured runner back running again

Debilitating injuries can impact quality of life long after the injury has occurred and healed, producing long-term pain and limited mobility. Individuals recuperating from a surgery or other procedure may want explore different options to getting back on their feet after an injury.

23 Dec 2010

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Ligand Pharmaceuticals Incorporated announced today that its partner Pfizer, Inc. has granted a sublicense to a multi-national pharmaceutical company for Tanaproget, also known as NSP-989. As a result, Ligand will receive an upfront payment of $1 million from Pfizer. Ligand is entitled to clinical and regulatory milestone payments from Pfizer as Tanaproget advances through the development process, as well as tiered royalties on net sales.

23 Dec 2010

Gifts to help navigate daily routine best for people living with chronic conditions

For those living with chronic conditions, the best holiday gift is something that will make navigating the daily routine easier.

22 Dec 2010

Gold nanoparticles show great potential for tumour targeted drug delivery

The World Gold Council (WGC) is delighted with the successful phase 1 clinical trial of a unique nanomedicine that uses nanoparticles of gold as the core of a delivery system for tumour targeted drug delivery.

22 Dec 2010

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda and its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ("TPNA"), have completed settlements with all defendants in patent litigation brought against the companies in response to their Abbreviated New Drug Applications ("ANDAs") for generic ACTOS® (pioglitazone HCl), ACTOplus met® (pioglitazone HCl and metformin HCl), and duetact® (pioglitazone HCl and glimepiride).

22 Dec 2010

Ramius/RP Group extend tender offer to acquire Cypress Bioscience

Ramius V&O Acquisition LLC, affiliates of Ramius LLC (collectively, "Ramius") and affiliates of Royalty Pharma (together with Ramius and Purchaser, the "Ramius/RP Group") announced today that the Ramius/RP Group is extending its previously announced tender offer to acquire all of the outstanding shares of common stock of Cypress Bioscience, Inc., a pharmaceutical company engaged in the development of innovative drugs to treat central nervous system (CNS) disorders, until Midnight, January 5, 2011, unless the offer is otherwise extended.

22 Dec 2010

Altering balance among immune system cells could hold potential for T2D-associated inflammation treatment

Researchers from Boston University School of Medicine (BUSM) have demonstrated that certain T cells require input from monocytes in order to maintain their pro-inflammatory response in people with type 2 diabetes (T2D). The study also showed, for the first time, how a loss in homeostasis in this group of T cells most likely promotes chronic inflammation associated with T2D.

22 Dec 2010

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

The Coalition for Pulmonary Fibrosis announced to more than 128,000 patients news that the first drug for the treatment of the deadly lung disease Pulmonary Fibrosis has passed a major hurdle in the European regulatory process and is likely to be approved in all 27 member countries of the European Union.

22 Dec 2010

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

In its recently released annual 2010 update, ChartTrends®: Biologics in Rheumatoid Arthritis, BioTrends Research Group, Inc. finds that newer biologic agents such as UCB's Cimzia and Centocor OrthoBiotech's Simponi, although lagging in overall market share, have begun to penetrate the first line biologic position primarily at the expense of Pfizer/Amgen's Enbrel and Abbott's Humira.

21 Dec 2010

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

Genzyme Corporation today provided an extensive briefing on the market potential of alemtuzumab for multiple sclerosis at an event for investors and analysts in New York.

21 Dec 2010

New research sheds light on complex regulatory pathways for effective innate immune system

New research by scientists at the University of California, San Diego School of Medicine and Skaggs School of Pharmacy and Pharmaceutical Sciences reveals that the immune system has an effective backup plan to protect the body from infection when the "master regulator" of the body's innate immune system fails.

21 Dec 2010

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Incyte Corporation announced today positive top-line results from COMFORT-I, the pivotal Phase III clinical trial of INCB18424 (also known as INC424) in patients with myelofibrosis (MF) being conducted under a Food and Drug Administration (FDA) Special Protocol Assessment (SPA) Agreement. COMFORT-I (COntrolled MyeloFibrosis Study with ORal JAK Inhibitor Treatment) is a double-blind, placebo-controlled Phase III trial involving 309 patients.

21 Dec 2010

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

New research finds pattern for detecting 'false-positive' ANA results

Interventions aimed at infants improve school readiness and achievement

Vitamin D deficiency could be linked to development of certain autoimmune lung diseases

New ATS guidelines for treating fungal infection in adult pulmonary and critical care patients

Sleep-deprived physicians not to perform elective surgeries without patient's consent

Centocor Ortho Biotech files REMICADE sBLA for ulcerative colitis in pediatric patients

CEL-SCI initiates Multikine Phase III trail for head and neck cancer

Santarus, Pharming submit RHUCIN BLA to FDA for treatment of HAE attacks

Herbal pain medication gets fractured runner back running again

Pfizer's sublicensing of Tanaproget triggers $1 million upfront payment to Ligand

Gifts to help navigate daily routine best for people living with chronic conditions

Gold nanoparticles show great potential for tumour targeted drug delivery

Takeda completes settlements in patent litigation over generic ACTOS, ACTOplus met, and duetact ANDAs

Ramius/RP Group extend tender offer to acquire Cypress Bioscience

Altering balance among immune system cells could hold potential for T2D-associated inflammation treatment

CHMP recommends to grant marketing authorization for Espriet drug against PF to CPF

UCB's Cimzia and Centocor's Simponi penetrate first line biologic position in RA

Genzyme provides information on peak sale of alemtuzumab for multiple sclerosis

New research sheds light on complex regulatory pathways for effective innate immune system

Positive results from Incyte's COMFORT-I INCB18424 pivotal Phase III clinical trial in myelofibrosis

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Arthritis & Rheumatology News and Research

Latest Arthritis & Rheumatology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in